Literature DB >> 18982242

The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Kun Yang1, Guang-Rong Xie, Yi-Qiu Hu, Fu-Qiang Mao, Lin-Yan Su.   

Abstract

S100B protein is a calcium-binding protein mostly derived from glial cells, which exerts trophic or toxic effects on neural cell depending on its concentration. It has been reported that S100B played an important role as a potential marker in psychiatric disorders. Thus, we will explore the clinical implication of S100B in major depression, especially the effect of gender and numbers of depressive episodes on S100B. The levels of serum S100B were measured with enzyme-linked immunosorbent assay (ELISA) in 54 patients with major depression and 35 age-matched healthy controls. The S100B levels in major depressed patients were significantly higher than those in controls. The serum S100B levels in female patients were significantly higher than those in male patients. Patients with recurrent depressive episodes had significantly higher S100B levels than those in first-episode depression. Serum S100B levels were significantly positive related with the numbers of depressive episode, family history and cognitive disturbance scores. These findings confirmed an increase in serum S100B levels in major depressive patients and presence of a sexual dimorphism. Moreover, numbers of depressive episodes in depression seemed to have an additional increasing effect on S100B levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982242     DOI: 10.1007/s00702-008-0130-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  39 in total

1.  Neuronal plasticity and survival in mood disorders.

Authors:  R S Duman; J Malberg; S Nakagawa; C D'Sa
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

2.  Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.

Authors:  R Machado-Vieira; D R Lara; L V C Portela; C A Gonçalves; J C Soares; F Kapczinski; D O Souza
Journal:  Eur Neuropsychopharmacol       Date:  2002-06       Impact factor: 4.600

3.  Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells.

Authors:  G Rajkowska
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

4.  Increased serum S100B protein in schizophrenia: a study in medication-free patients.

Authors:  D R Lara; C S Gama; P Belmonte-de-Abreu; L V Portela; C A Gonçalves; M Fonseca; S Hauck; D O Souza
Journal:  J Psychiatr Res       Date:  2001 Jan-Feb       Impact factor: 4.791

5.  The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.

Authors:  Guenter Hetzel; Olaf Moeller; Stefan Evers; Andreas Erfurth; Gerald Ponath; Volker Arolt; Matthias Rothermundt
Journal:  Psychopharmacology (Berl)       Date:  2004-08-14       Impact factor: 4.530

Review 6.  S100B in schizophrenic psychosis.

Authors:  Matthias Rothermundt; Gerald Ponath; Volker Arolt
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

7.  S100B and response to treatment in major depression: a pilot study.

Authors:  Volker Arolt; Marion Peters; Andreas Erfurth; Martin Wiesmann; Ulrich Missler; Sebastian Rudolf; Holger Kirchner; Matthias Rothermundt
Journal:  Eur Neuropsychopharmacol       Date:  2003-08       Impact factor: 4.600

8.  S100B is increased in mood disorders and may be reduced by antidepressive treatment.

Authors:  Matthias L Schroeter; Hashim Abdul-Khaliq; Albert Diefenbacher; Ingolf E Blasig
Journal:  Neuroreport       Date:  2002-09-16       Impact factor: 1.837

Review 9.  Recurrent brief depression: the Zurich Study.

Authors:  J Angst; B Hochstrasser
Journal:  J Clin Psychiatry       Date:  1994-04       Impact factor: 4.384

10.  Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.

Authors:  Detlef E Dietrich; Ute Hauser; Marion Peters; Yuanyuan Zhang; Martin Wiesmann; Mark Hasselmann; Sebastian Rudolf; Oliver Jüngling; Holger Kirchner; Thomas F Münte; Volker Arolt; Hinderk M Emrich; Sönke Johannes; Matthias Rothermundt
Journal:  Neurosci Lett       Date:  2004-01-02       Impact factor: 3.046

View more
  12 in total

1.  Association of Brain Cortical Changes With Relapse in Patients With Major Depressive Disorder.

Authors:  Dario Zaremba; Katharina Dohm; Ronny Redlich; Dominik Grotegerd; Robert Strojny; Susanne Meinert; Christian Bürger; Verena Enneking; Katharina Förster; Jonathan Repple; Nils Opel; Bernhard T Baune; Pienie Zwitserlood; Walter Heindel; Volker Arolt; Harald Kugel; Udo Dannlowski
Journal:  JAMA Psychiatry       Date:  2018-05-01       Impact factor: 21.596

2.  Mood disorders are glial disorders: evidence from in vivo studies.

Authors:  Matthias L Schroeter; Hashim Abdul-Khaliq; Julia Sacher; Johann Steiner; Ingolf E Blasig; Karsten Mueller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-05-27

3.  S100B and homocysteine in the acute alcohol withdrawal syndrome.

Authors:  Dirk Wedekind; Karolin Neumann; Peter Falkai; Berend Malchow; Kirsten Rita Engel; Katja Jamrozinski; Ursula Havemann-Reinecke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-01       Impact factor: 5.270

4.  Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure.

Authors:  Sarah K Williams; Jean M Lauder; Josephine M Johns
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

Review 5.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

6.  Blood levels of S-100 calcium-binding protein B, high-sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: prospective cohort nested within a randomized, controlled trial.

Authors:  Daniel M Pearlman; Jeremiah R Brown; Todd A MacKenzie; Felix Hernandez; Souhel Najjar
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

7.  Evaluation of oxidant, antioxidant, and S100B levels in patients with conversion disorder.

Authors:  Hasan Büyükaslan; Sultan Basmacı Kandemir; Mehmet Asoğlu; Halil Kaya; Mehmet Tahir Gökdemir; İbrahim Fatih Karababa; Fatih Güngörmez; Fethiye Kılıçaslan; Emin Şavik
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-13       Impact factor: 2.570

8.  Serum S100B levels in patients with depression.

Authors:  Parul Arora; Rajesh Sagar; Manju Mehta; Pooja Pallavi; Subhadra Sharma; Asok Kumar Mukhopadhyay
Journal:  Indian J Psychiatry       Date:  2019 Jan-Feb       Impact factor: 1.759

9.  First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression.

Authors:  Maryna Polyakova; Christian Sander; Katrin Arelin; Leonie Lampe; Tobias Luck; Melanie Luppa; Jürgen Kratzsch; Karl-Titus Hoffmann; Steffi Riedel-Heller; Arno Villringer; Peter Schoenknecht; Matthias L Schroeter
Journal:  Front Cell Neurosci       Date:  2015-10-09       Impact factor: 5.505

Review 10.  Serum S100B represents a new biomarker for mood disorders.

Authors:  Matthias L Schroeter; Julia Sacher; Johann Steiner; Peter Schoenknecht; Karsten Mueller
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.